spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

MedPharm Expands Relationship With Novan On Formulation Science

MedPharm


MedPharm Ltd, a leader in topical and transdermal drug delivery, has expanded its relationship with the NASDAQ listed biopharmaceutical company Novan Inc.

MedPharm has previously supported Novan by testing the company’s unique formulations using its proprietary in vitro models to optimise Novan’s formulations and de-risk product development.

The newly expanded agreement between the companies will broaden the relationship to include development of formulations and selection of product candidates, cost-effective product target screening and the development of in vitro models focused on Novan’s nitric oxide product technology.

“MedPharm is delighted to be able to support Novan in advancing and broadening its product pipeline,” commented Eugene Ciolfi, MedPharm’s President & CEO. “Our new agreement allows us to react quickly to changes in requirements and makes full use of MedPharm’s comprehensive services for de-risking Novan’s product development”.

“Novan recognises MedPharm has in-depth experience in developing new topical products fit for commercialisation”, added Paula Brown Stafford, Novan’s President and Chief Operating Officer. “The team’s responsiveness, rigorous scientific approach and specialised knowledge makes MedPharm an ideal partner to help Novan achieve its objectives.”

About MedPharm

MedPharm is the world’s leading contract provider of topical and transdermal product design and formulation development services. MedPharm are experts at reducing risk and accelerating development times for generic and proprietary pharmaceutical customers through their unique, cost-effective and industry-leading performance testing models. Well established as the global leaders in dermatology, nail, mucosal membrane, and transdermal product development, MedPharm can also offer innovative solutions for ophthalmic and airway preparations recognized for their scientific rigor by regulators and investors. MedPharm has fully established R&D centers in the USA and UK and has its global HQ in Guildford, UK.

About Novan

Novan, Inc. is a clinical development-stage biotechnology company focused on leveraging nitric oxide’s naturally occurring anti-microbial and immunomodulatory mechanisms of action to treat a range of diseases with significant unmet needs. We believe that our ability to deploy nitric oxide in a solid form, on demand and in localized formulations allows us the potential to improve patient outcomes in a variety of dermatological, women’s health and gastrointestinal diseases.
phone 01483 457580
email busdev@medpharm.com
web https://www.medpharm.com/en/
email Unit 1, Chancellor Court, 50 Occam Rd, Guildford GU2 7AB
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Wool packaging firm’s green scheme goes ‘beyond recycling’

An award-winning company that has spent more than 10 years innovating in sustainable packaging has launched a scheme that it says goes ‘beyond recycling’ – by allowing the end user to return their packaging directly to them to be used again.
More info >>


White Papers

Analysis of Biopharmaceuticals to Conform to ICHQ6B

RSSL

Worldwide, the pharmaceuticals market is anticipated to grow from more than USD 782 billion in 2011 to approach a value of just over USD 971 billion by the end of 2016, registering a CAGR of over 24%. In 2010 the average medicines expenditure per person within the UK was £271, and this is expected to increase with the ageing population. A significant and increasing proportion of these sales are protein-based biotherapeutics or biomolecules. Currently, these account for 19% of the total market, and are growing at twice the rate of traditional small molecule pharmaceuticals. It is predicted that close to 50% of the top 100 pharmaceutical products will be biomolecules by 2016. By far the largest segment of the biopharmaceutical market is the monoclonal antibody (MAb) with an estimated share of 25.6%, which corresponds to USD 51.1 billion.
More info >>

Industry Events

CPhI Worldwide

5-7 November 2019, Frankfurt, Germany

Join the World's Largest Pharma Event As it Celebrates its 30th Anniversary! Taking place from 5-7 November 2019 in Frankfurt, Germany, the event will bring together more than 45,000 visiting pharma professionals from around the globe and over 2,500 exhibiting pharma companies from every stage of the pharmaceutical supply chain - from ingredients and machinery to outsourcing services, packaging and more!
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement